Form: 8-K

Current report filing

September 20, 2023

Documents

0001335105 false 0001335105 2023-09-20 2023-09-20 0001335105 LIXT:CommonStockParValue0.0001PerShareMember 2023-09-20 2023-09-20 0001335105 LIXT:WarrantsToPurchaseCommonStockParValue0.0001PerShareMember 2023-09-20 2023-09-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): September 20, 2023

 

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

delaware   001-39717   20-2903526

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification Number)

 

680 East Colorado Boulevard, Suite 180

Pasadena California 91101

(Address of principal executive offices)

 

(631) 830-7092

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share  

LIXT

  

The NASDAQ Stock Market, LLC
Warrants to Purchase Common Stock, par value $0.0001 per share  

LIXTW

  

The NASDAQ Stock Market, LLC

 

 

 

 

 

 

Item 8.01. Other Events.

 

On September 20, 2023, the Company issued a press release regarding a Phase 1b collaborative trial to be conducted at the University of Texas MD Anderson Cancer Center to assess whether adding LB-100, the Company’s lead compound, to GSK’s Dostarlimab enhances the effectiveness in the treatment of ovarian clear cell carcinoma.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) There is filed as part of this report the exhibit listed on the accompanying Index to Exhibits, which exhibit is incorporated herein by reference.

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: September 20, 2023

LIXTE BIOTECHNOLOGY HOLDINGS, INC.
     
  By: /s/ JOHN S. KOVACH
   

John S. Kovach, Chief Executive Officer

 

3

 

 

INDEX TO EXHIBITS

 

Exhibit No.

 

 Description
     
99.1   Press Release regarding a Phase 1b collaborative trial to be conducted at the University of Texas MD Anderson Cancer Center to assess whether adding LB-100, the Company’s lead compound, to GSK’s Dostarlimab enhances the effectiveness in the treatment of ovarian clear cell carcinoma.
     
104  

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

4